⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BTAI News
BioXcel Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
BTAI
BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting
globenewswire.com
BTAI
Levi & Korsinsky, LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of BioXcel Therapeutics, Inc.
globenewswire.com
BTAI
Exosome Research Market Analysis, Opportunity Forecasts Report 2026-2035
globenewswire.com
CRBP
BTAI
Form 8-K
sec.gov
BTAI
BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering
globenewswire.com
BTAI
BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering
globenewswire.com
BTAI
BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal
globenewswire.com
BTAI
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia
globenewswire.com
BTAI
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting
globenewswire.com
BTAI